Hiroki Ishihara1, Toshio Takagi2, Tsunenori Kondo3, Hironori Fukuda2, Kazuhiko Yoshida2, Junpei Iizuka2, Kazunari Tanabe2. 1. Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. ishihara.hiroki@twmu.ac.jp. 2. Department of Urology, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. 3. Department of Urology, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan.
Abstract
BACKGROUND: Sarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia. OBJECTIVE: To evaluate the prognostic impact of changes in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Sixty-nine patients were evaluated retrospectively. The skeletal muscle index (SMI) was calculated based on computed tomography images obtained before the initiation (pre-treatment SMI) and after two cycles of sunitinib treatment (post-treatment SMI). The change in SMM was evaluated based on the value of ΔSMI, which was calculated as [(posttreatment SMI - pretreatment SMI)/ pretreatment SMI] × 100. Oncological outcomes were compared between patients with ΔSMI <0 (SMM decrease) and ΔSMI ≥0 (SMM maintenance). RESULTS: A decrease in SMM was observed in 38 patients (55.1%). Progression-free survival (PFS) and overall survival (OS) after sunitinib therapy initiation were significantly shorter in patients with ΔSMI <0 than in those with ΔSMI ≥0 (median PFS: 9.53 vs. 28.4 months, p < 0.0001; OS: 19.8 vs. 52.6 months, p = 0.0001). ΔSMI was an independent predictive factor for PFS (HR 3.25, 95% CI 1.74-6.29, p = 0.0002) and OS (HR 4.53, 95% CI 2.15-10.5, p < 0.0001). The objective response rate was significantly lower in patients with ΔSMI <0 than in those with ΔSMI ≥0 (23.7% vs. 51.6%, p = 0.0164). CONCLUSION: Decreased SMM during first-line sunitinib therapy can be an effective marker of outcome prediction for mRCC.
BACKGROUND:Sarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia. OBJECTIVE: To evaluate the prognostic impact of changes in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Sixty-nine patients were evaluated retrospectively. The skeletal muscle index (SMI) was calculated based on computed tomography images obtained before the initiation (pre-treatment SMI) and after two cycles of sunitinib treatment (post-treatment SMI). The change in SMM was evaluated based on the value of ΔSMI, which was calculated as [(posttreatment SMI - pretreatment SMI)/ pretreatment SMI] × 100. Oncological outcomes were compared between patients with ΔSMI <0 (SMM decrease) and ΔSMI ≥0 (SMM maintenance). RESULTS: A decrease in SMM was observed in 38 patients (55.1%). Progression-free survival (PFS) and overall survival (OS) after sunitinib therapy initiation were significantly shorter in patients with ΔSMI <0 than in those with ΔSMI ≥0 (median PFS: 9.53 vs. 28.4 months, p < 0.0001; OS: 19.8 vs. 52.6 months, p = 0.0001). ΔSMI was an independent predictive factor for PFS (HR 3.25, 95% CI 1.74-6.29, p = 0.0002) and OS (HR 4.53, 95% CI 2.15-10.5, p < 0.0001). The objective response rate was significantly lower in patients with ΔSMI <0 than in those with ΔSMI ≥0 (23.7% vs. 51.6%, p = 0.0164). CONCLUSION: Decreased SMM during first-line sunitinib therapy can be an effective marker of outcome prediction for mRCC.
Authors: Shlomit Strulov Shachar; Allison M Deal; Marc Weinberg; Kirsten A Nyrop; Grant R Williams; Tomohiro F Nishijima; Julia M Benbow; Hyman B Muss Journal: Clin Cancer Res Date: 2016-08-03 Impact factor: 12.531
Authors: Casper Simonsen; Pieter de Heer; Eik D Bjerre; Charlotte Suetta; Pernille Hojman; Bente K Pedersen; Lars B Svendsen; Jesper F Christensen Journal: Ann Surg Date: 2018-07 Impact factor: 12.969
Authors: Louise E Daly; Éadaoin B Ní Bhuachalla; Derek G Power; Samantha J Cushen; Karl James; Aoife M Ryan Journal: J Cachexia Sarcopenia Muscle Date: 2018-01-09 Impact factor: 12.910
Authors: Iris J G Rutten; David P J van Dijk; Roy F P M Kruitwagen; Regina G H Beets-Tan; Steven W M Olde Damink; Toon van Gorp Journal: J Cachexia Sarcopenia Muscle Date: 2016-03-07 Impact factor: 12.910